Intellia Therapeutics, Inc. (0JBU.L)
USD 12.59
(-6.07%)
USD 12.59
(-6.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -398.79 Million USD | -38.72% |
| 2022 | 44.54 Million USD | 70.28% |
| 2021 | 26.16 Million USD | 128.31% |
| 2020 | -92.41 Million USD | -41.5% |
| 2019 | -65.31 Million USD | -11.3% |
| 2018 | -58.68 Million USD | -41.3% |
| 2017 | -41.53 Million USD | -170.36% |
| 2016 | -15.36 Million USD | -199.67% |
| 2015 | -5.12 Million USD | -209.26% |
| 2014 | -1.65 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 26.42 Million USD | 702.85% |
| 2024 Q2 | 4.35 Million USD | -83.51% |
| 2023 Q2 | 11.42 Million USD | 8.22% |
| 2023 FY | 27.29 Million USD | -38.72% |
| 2023 Q4 | -4.38 Million USD | -145.18% |
| 2023 Q1 | 10.55 Million USD | -8.54% |
| 2023 Q3 | 9.7 Million USD | -15.07% |
| 2022 Q1 | 9.49 Million USD | -13.45% |
| 2022 Q4 | 11.54 Million USD | 113.84% |
| 2022 Q3 | -83.38 Million USD | -783.88% |
| 2022 Q2 | 12.19 Million USD | 28.37% |
| 2022 FY | 44.54 Million USD | 70.28% |
| 2021 Q3 | -53.28 Million USD | -1.81% |
| 2021 Q4 | 10.97 Million USD | 120.6% |
| 2021 FY | 26.16 Million USD | 128.31% |
| 2021 Q1 | -32.83 Million USD | -3.78% |
| 2021 Q2 | -52.33 Million USD | -59.4% |
| 2020 Q4 | -31.63 Million USD | -80.41% |
| 2020 FY | -92.41 Million USD | -41.5% |
| 2020 Q1 | -21.73 Million USD | -4.52% |
| 2020 Q3 | -17.53 Million USD | 18.47% |
| 2020 Q2 | -21.5 Million USD | 1.04% |
| 2019 Q3 | -16.89 Million USD | -17.81% |
| 2019 FY | -65.31 Million USD | -11.3% |
| 2019 Q1 | -13.27 Million USD | -10.28% |
| 2019 Q4 | -20.79 Million USD | -23.07% |
| 2019 Q2 | -14.34 Million USD | -8.03% |
| 2018 Q4 | -12.03 Million USD | 23.95% |
| 2018 FY | -58.68 Million USD | -41.3% |
| 2018 Q3 | -15.82 Million USD | -0.25% |
| 2018 Q2 | -15.79 Million USD | -5.1% |
| 2018 Q1 | -15.02 Million USD | -3.6% |
| 2017 FY | -41.53 Million USD | -170.36% |
| 2017 Q3 | -10.16 Million USD | -5.35% |
| 2017 Q2 | -9.64 Million USD | -33.7% |
| 2017 Q4 | -14.5 Million USD | -42.68% |
| 2017 Q1 | -7.21 Million USD | -26.51% |
| 2016 FY | -15.36 Million USD | -199.67% |
| 2016 Q4 | -5.7 Million USD | -90.64% |
| 2016 Q3 | -2.99 Million USD | 6.99% |
| 2016 Q2 | -3.21 Million USD | 6.7% |
| 2016 Q1 | -3.44 Million USD | -28.56% |
| 2015 FY | -5.12 Million USD | -209.26% |
| 2015 Q3 | -1.77 Million USD | -200.51% |
| 2015 Q4 | -2.68 Million USD | -51.53% |
| 2015 Q1 | -85 Thousand USD | 94.24% |
| 2015 Q2 | -589 Thousand USD | -592.94% |
| 2014 FY | -1.65 Million USD | 0.0% |
| 2014 Q4 | -1.47 Million USD | 0.0% |
| 2014 Q2 | -11 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | -300.685% |
| Dynavax Technologies Corporation | 182.11 Million USD | 318.977% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 176.143% |
| Perrigo Company plc | 1.68 Billion USD | 123.732% |
| Illumina, Inc. | 2.74 Billion USD | 114.533% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 102.62% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | -4068.869% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 101.504% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 107.612% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 4071.261% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 103.529% |
| Unity Biotechnology, Inc. | -19.69 Million USD | -1924.438% |
| Waters Corporation | 1.76 Billion USD | 122.643% |
| Biogen Inc. | 7.3 Billion USD | 105.461% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | -779.854% |
| Evolus, Inc. | 140.52 Million USD | 383.787% |
| Adicet Bio, Inc. | -6.09 Million USD | -6439.751% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 2795.647% |
| bluebird bio, Inc. | -4.03 Million USD | -9795.633% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 645.792% |
| FibroGen, Inc. | 128.9 Million USD | 409.373% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 111.509% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | -1179.512% |
| Homology Medicines, Inc. | -7.22 Million USD | -5416.586% |
| Geron Corporation | -123.5 Million USD | -222.902% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 126.273% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 210.155% |
| Myriad Genetics, Inc. | 476.4 Million USD | 183.71% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -136473.288% |
| Zoetis Inc. | 5.83 Billion USD | 106.836% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 132150.993% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 118.385% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 120.941% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 104.633% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -131515.182% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 151.225% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -127310.224% |
| Verastem, Inc. | -62 Thousand USD | -643116.129% |
| Nektar Therapeutics | 53.47 Million USD | 845.716% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 263.083% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | -367.98% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 136.486% |
| OPKO Health, Inc. | 318.12 Million USD | 225.357% |
| Exelixis, Inc. | 1.75 Billion USD | 122.689% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 121.587% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 183.799% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| uniQure N.V. | 2.21 Million USD | 18104.244% |
| Imunon, Inc. | -720 Thousand USD | -55287.671% |
| Blueprint Medicines Corporation | 236.58 Million USD | 268.563% |
| Insmed Incorporated | 239.63 Million USD | 266.417% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 162.616% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 2402.639% |
| TG Therapeutics, Inc. | 219.1 Million USD | 282.008% |
| Incyte Corporation | 3.44 Billion USD | 111.591% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 215.962% |